‘Building The Plane While Flying It’: Cell And Gene Therapy Makers Prepare For MFN Pricing, Tariffs

 
• By Mandy Jackson
  
Physician-administered and Medicaid-covered drugs, like cell and gene therapies, are most exposed to MFN policy (Shutterstock)

More from Scrip

More from Drug Pricing